You searched for "surgery"
Inguino-scrotal sarcomas
A sarcoma is a malignant tumour that originates from mesenchymal cells such as adipose tissue, bone, cartilage and smooth muscle. Although these tumours histologically do not originate from the urogenital tract, urologists are often involved in their diagnosis and management...Peno-scrotal extramammary Paget’s disease
Epidemiology Extramammary Paget’s disease (EMP) is a rare intraepithelial neoplasm, which is rarely invasive and has an incidence of six per million person-years as calculated by a European SEER analysis [1]. It usually affects apocrine gland-bearing areas, especially the vulvar,...Urology ST3 interview update and top tips
This article, written by a Urology ST3 from the West of Scotland Deanery, aims to give the reader an insight into the ST3 interview process along with some helpful hints for those about to undertake the challenge. The aims of...
Solifenacin for children and adolescents with overactive bladders
Solifenacin (VESIcare®) is the second-line anti-muscarinic medication of choice for my patients with overactive bladder (oxybutynin being my initial choice). However, currently, it remains unlicensed for use in children. Newgreen et al. have evaluated the long-term safety and efficacy of...
The challenge of psychological problems in enuresis treatment
The first sentence of the conclusion of this review article reads: “In the past decade the role of psychological factors in the pathogenesis of nocturnal enuresis has changed from a primary causal factor to a consequence or comorbidity.” The authors...
Dual therapy for OAB in children
Overactive bladder (OAB) is a disorder frequently encountered by the paediatric urologist. Morin et al. report the results of the first known study on the efficacy of mirabegron (a β3 adrenoceptor agonist) as add-on therapy in paediatric patients with refractory...
Solifenacin and mirabegron are safe and effective in combination
Antimuscarinic agents remain the mainstay of medical management of bladder overactivity. Limited somewhat by their tolerability, the new agent mirabegron, a β3-adrenoreceptor agonist, has been approved as an alternative. There is little known however about the possible synergistic effects of...
